ResultsIQ

ResultsIQ › Latest results › Max Healthcare Institute Limited

Max Healthcare Institute Limited strategy deck summary

NSE: MAXHEALTH · BSE: 543220

Strategy deck of 31 May 2025, summarised by AI from the filing.

550 beds acquired in Q4 FY24 at Lucknow and Nagpur delivered 41% revenue and 96% EBITDA growth YoY

Key takeaways

  1. New Units growth 550 beds acquired in Q4 FY24 at Lucknow and Nagpur delivered 41% revenue and 96% EBITDA growth YoY
  2. Max Lab growth Max Lab net revenue ₹175 cr in FY25, 45% CAGR since FY18
  3. Margin pressure Operating EBITDA margin declined to 26.8% in FY25 from 27.8% in FY24

Original filing on BSE

Max Healthcare Institute Limited Q1 FY27 results

As filed: Revenue ₹2,366 cr (+17% year on year), EBITDA ₹598 cr (+15% year on year), PAT ₹323 cr (+5% year on year), EBITDA margin 25.3% (−45 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹2,143 cr (+12% year on year), EBITDA ₹606 cr (+18% year on year), PAT ₹342 cr (+7% year on year), EBITDA margin 28.3% (+149 bps). Score 43 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 149 bps year on year. Revenue rose ₹233 cr on a year ago, against ₹487 cr the year before. Share price after the results: +0.3% in 29 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹2,068 cr (+11% year on year), EBITDA ₹538 cr (+8% year on year), PAT ₹301 cr (+8% year on year), EBITDA margin 26.0% (−73 bps). Score 28 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit before exceptional items growth was below it. EBITDA margin fell 73 bps year on year. Revenue fell 3% from last quarter. Revenue rose ₹200 cr on a year ago, against ₹533 cr the year before. Share price after the results: +1.6% in 29 days (Nifty 500: −4.5%).
  • Q2 FY26: Revenue ₹2,135 cr (+25% year on year), EBITDA ₹575 cr (+27% year on year), PAT ₹491 cr (+74% year on year), EBITDA margin 26.9% (+51 bps). Score 69 of 100, Above trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was well above it. EBITDA margin rose 51 bps year on year. Tax rate -10%. Consolidated profit +74% but standalone -31%. Revenue rose ₹428 cr on a year ago, more than the ₹344 cr it added the year before. Share price after the results: −2.0% in 28 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹2,028 cr (+31% year on year), EBITDA ₹522 cr (+35% year on year), PAT ₹308 cr (+31% year on year), EBITDA margin 25.7% (+66 bps). Score 83 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 66 bps year on year. Profit fell 3% from last quarter. Revenue rose ₹485 cr on a year ago, more than the ₹258 cr it added the year before. Share price after the results: −6.1% in 30 days (Nifty 500: +2.8%).
  • Q4 FY25: Revenue ₹1,910 cr (+34% year on year), EBITDA ₹512 cr (+34% year on year), PAT ₹319 cr (+27% year on year), EBITDA margin 26.8% (−4 bps). Score 78 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin was flat year on year. Consolidated profit +27% but standalone -27%. Revenue rose ₹487 cr on a year ago, more than the ₹208 cr it added the year before. Share price after the results: −2.1% in 30 days (Nifty 500: −0.4%).
  • Q3 FY25: Revenue ₹1,868 cr (+40% year on year), EBITDA ₹500 cr (+30% year on year), PAT ₹239 cr (+6% year on year), EBITDA margin 26.8% (−215 bps). Score 71 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit before exceptional items growth was below it. EBITDA margin fell 215 bps year on year.
  • Q2 FY25: Revenue ₹1,707 cr (+25% year on year), EBITDA ₹451 cr (+16% year on year), PAT ₹282 cr (+2% year on year), EBITDA margin 26.4% (−205 bps). Score 52 of 100, In line with trend. EBITDA margin fell 205 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Max Healthcare Institute Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.